Mrinal M. Gounder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mrinal M. Gounder has a total of 655 co-authors. Here are the top co-authors by number of shared publications:
- Ping Chi
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
139 shared publications - Sandra P. D’ Angelo
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
138 shared publications - William D. Tap
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
138 shared publications - Ciara M. Kelly
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
135 shared publications - Mark Andrew Dickson
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
133 shared publications - Mary Louise Keohan
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
133 shared publications
Latest Publications
- Open Access
Evaluation of the Clinicopathologic and Genomic Features of CNS Metastases in Soft Tissue Sarcoma
Background: The incidence and risk factors for central nervous system (CNS) metastases in soft tissue sarcoma (STS) are poorly defined. We evaluated the frequency of CNS metastases in STS and associated clinicopathologic and genomic factors. Methods: This retrospective study used the Memorial Sloan Kettering Cancer Center institutional cBioPortal database. Patients with invasive STS, including gastrointestinal stromal tumor, were included. CNS metastases were identified using natural language processing-derived radiology annotations and confirmed by manual chart review. Cumulative incidence was estimated with death as a competing event. Clinicopathologic and genomic associations were evaluated using Firth logistic regression with correction for multiplicity; post-CNS metastasis survival was estimated using Kaplan–Meier analysis. Results: A total of 5379 patients were included. CNS metastases were identified in 161 patients (3.0%), with a 10-year cumulative incidence of 4.5% after accounting for death as a competing event. Median overall survival after CNS metastasis was 4.76 months (95% CI, 3.9–7.5). In one-versus-rest analyses, increased odds of CNS metastasis were observed for alveolar soft part sarcoma (OR 16.61, 95% CI 7.21–35.81; q < 0.001), rhabdomyosarcoma (OR 2.44, 95% CI 1.42–3.97; q = 0.007), non-uterine leiomyosarcoma (OR 2.24, 95% CI 1.45–3.34; q = 0.003), extremity primaries (OR 2.20, 95% CI 1.58–3.05; q < 0.001), head and neck primaries (OR 2.11, 95% CI 1.26–3.35; q = 0.017), and PDGFRB alterations (OR 4.90, 95% CI 2.29–9.41; q = 0.016). KIT alterations were associated with lower odds (OR 0.10, 95% CI 0.02–0.29; q < 0.001). Conclusions: CNS metastases in STS were uncommon but associated with poor survival, with risk varying by histology and primary site.
Open AccessEvaluation of the Clinicopathologic and Genomic Features of CNS Metastases in Soft Tissue Sarcoma
Background: The incidence and risk factors for central nervous system (CNS) metastases in soft tissue sarcoma (STS) are poorly defined. We evaluated the frequency of CNS metastases in STS and associated clinicopathologic and genomic factors. Methods: This retrospective study used the Memorial Sloan Kettering Cancer Center institutional cBioPortal database. Patients with invasive STS, including gastrointestinal stromal tumor, were included. CNS metastases were identified using natural language processing-derived radiology annotations and confirmed by manual chart review. Cumulative incidence was estimated with death as a competing event. Clinicopathologic and genomic associations were evaluated using Firth logistic regression with correction for multiplicity; post-CNS metastasis survival was estimated using Kaplan–Meier analysis. Results: A total of 5379 patients were included. CNS metastases were identified in 161 patients (3.0%), with a 10-year cumulative incidence of 4.5% after accounting for death as a competing event. Median overall survival after CNS metastasis was 4.76 months (95% CI, 3.9–7.5). In one-versus-rest analyses, increased odds of CNS metastasis were observed for alveolar soft part sarcoma (OR 16.61, 95% CI 7.21–35.81; q < 0.001), rhabdomyosarcoma (OR 2.44, 95% CI 1.42–3.97; q = 0.007), non-uterine leiomyosarcoma (OR 2.24, 95% CI 1.45–3.34; q = 0.003), extremity primaries (OR 2.20, 95% CI 1.58–3.05; q < 0.001), head and neck primaries (OR 2.11, 95% CI 1.26–3.35; q = 0.017), and PDGFRB alterations (OR 4.90, 95% CI 2.29–9.41; q = 0.016). KIT alterations were associated with lower odds (OR 0.10, 95% CI 0.02–0.29; q < 0.001). Conclusions: CNS metastases in STS were uncommon but associated with poor survival, with risk varying by histology and primary site.
- 10 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (32) , 3151-3162
RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial
PURPOSE: Desmoid tumors (DTs) are rare, often locally aggressive, connective tissue neoplasms with limited effective treatment options. We evaluated the safety and efficacy of varegacestat, an oral gamma-secretase inhibitor. METHODS: RINGSIDE phase II was an open-label, randomized, dose-finding trial of varegacestat in adults with histologically confirmed DT and disease progression. Participants were randomly assigned 1:1:1 to oral varegacestat 1.2-mg once-daily, 2-mg intermittent (once daily for 2 consecutive days with 5 consecutive days off), or 4-mg intermittent dose. The primary end point was safety. The secondary end point was change in tumor volume from baseline to week 16 per blinded independent central review. At the study end, participants who entered the open-label extension received the selected phase III dose (1.2 mg once daily). RESULTS: In total, 42 participants enrolled in the randomized trial (14 per dose arm). Median varegacestat exposure was 50.5 (range, 3.0-76.0) weeks. Forty-one (97.6%) participants reported treatment-related adverse events (AEs), of which 9 (21.4%) reported grade 3 AEs and none reported serious AEs. There were no grade 4/5 events. The median tumor volume reduction at week 16 was –51.91% for the 1.2-mg once-daily dose, –15.25% for the 2-mg intermittent dose and –9.50% for the 4-mg intermittent dose. The confirmed objective response rate (ORR) was 35.7%, 21.4%, and 21.4%, respectively. Among 29 (69%) participants who entered the open-label extension and received 1.2 mg once daily (median exposure, 102.0 [range, 3.0-169.0] weeks), the median best percent tumor volume change was –85.88% and the confirmed ORR increased to 57.1%. CONCLUSION: Varegacestat demonstrated clinically meaningful DT volume reduction and ORR with a manageable safety profile across dose regimens. The largest responses were seen with the 1.2-mg once-daily dose, which was selected for the RINGSIDE phase III trial.
- 10 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (32) , 3151-3162
RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial
PURPOSE: Desmoid tumors (DTs) are rare, often locally aggressive, connective tissue neoplasms with limited effective treatment options. We evaluated the safety and efficacy of varegacestat, an oral gamma-secretase inhibitor. METHODS: RINGSIDE phase II was an open-label, randomized, dose-finding trial of varegacestat in adults with histologically confirmed DT and disease progression. Participants were randomly assigned 1:1:1 to oral varegacestat 1.2-mg once-daily, 2-mg intermittent (once daily for 2 consecutive days with 5 consecutive days off), or 4-mg intermittent dose. The primary end point was safety. The secondary end point was change in tumor volume from baseline to week 16 per blinded independent central review. At the study end, participants who entered the open-label extension received the selected phase III dose (1.2 mg once daily). RESULTS: In total, 42 participants enrolled in the randomized trial (14 per dose arm). Median varegacestat exposure was 50.5 (range, 3.0-76.0) weeks. Forty-one (97.6%) participants reported treatment-related adverse events (AEs), of which 9 (21.4%) reported grade 3 AEs and none reported serious AEs. There were no grade 4/5 events. The median tumor volume reduction at week 16 was –51.91% for the 1.2-mg once-daily dose, –15.25% for the 2-mg intermittent dose and –9.50% for the 4-mg intermittent dose. The confirmed objective response rate (ORR) was 35.7%, 21.4%, and 21.4%, respectively. Among 29 (69%) participants who entered the open-label extension and received 1.2 mg once daily (median exposure, 102.0 [range, 3.0-169.0] weeks), the median best percent tumor volume change was –85.88% and the confirmed ORR increased to 57.1%. CONCLUSION: Varegacestat demonstrated clinically meaningful DT volume reduction and ORR with a manageable safety profile across dose regimens. The largest responses were seen with the 1.2-mg once-daily dose, which was selected for the RINGSIDE phase III trial.
- Open Access
- 3 September 2026
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (5)
Treatment patterns and outcomes in advanced clear cell sarcoma and gastrointestinal neuroectodermal tumors
Background: Clear cell sarcoma and gastrointestinal neuroectodermal tumor are ultra-rare soft tissue sarcomas with no established standard of care for advanced disease. Data evaluating outcomes of systemic therapy remain limited. We aimed to evaluate systemic therapy in patients with metastatic clear cell sarcoma and gastrointestinal neuroectodermal tumor treated at a tertiary referral institution. Methods: This is a retrospective, single-institution study of patients with metastatic clear cell sarcoma and gastrointestinal neuroectodermal tumor diagnosed between January 2000 and May 2025. The primary objective was to describe patterns of systemic therapy use, and secondary endpoints included overall survival (OS) and real-world progression-free survival (PFS). Survival outcomes were estimated using the Kaplan–Meier method. Hazard ratios were estimated using Cox proportional hazards models. Exploratory analyses evaluated outcomes by treatment class. Results: A total of 66 patients were included; 55 received systemic therapy. Median follow-up was 192 months, and patients received a median of 2 treatment lines with heterogeneous sequencing. Median OS was 18 months (95% CI = 13.6 to 28.0). In first-line analyses, tyrosine kinase inhibitor–based therapy and immune checkpoint inhibitors were associated with improved OS compared with doxorubicin-based chemotherapy (tyrosine kinase inhibitor: hazard ratio [HR] = 0.33, 95% CI = 0.14 to 0.79; P = .01; immune checkpoint inhibitor: HR = 0.39, 95% CI = 0.10 to 0.94; P = .04). Median first-line real-world PFS was 3.8 months (95% CI = 2.9 to 6.3), with no statistically significant differences between treatment classes. Nondoxorubicin–based chemotherapy was associated with shorter real-world PFS compared with doxorubicin regimens (HR = 4.1, 95% CI = 1.71 to 9.83; P < .001). Conclusions: Metastatic clear cell sarcoma and gastrointestinal neuroectodermal tumor is highly aggressive with limited effective systemic options. Outcomes remain poor, highlighting the need for novel therapies and collaborative studies.
- 3 September 2026
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (5)
Open AccessTreatment patterns and outcomes in advanced clear cell sarcoma and gastrointestinal neuroectodermal tumors
Background: Clear cell sarcoma and gastrointestinal neuroectodermal tumor are ultra-rare soft tissue sarcomas with no established standard of care for advanced disease. Data evaluating outcomes of systemic therapy remain limited. We aimed to evaluate systemic therapy in patients with metastatic clear cell sarcoma and gastrointestinal neuroectodermal tumor treated at a tertiary referral institution. Methods: This is a retrospective, single-institution study of patients with metastatic clear cell sarcoma and gastrointestinal neuroectodermal tumor diagnosed between January 2000 and May 2025. The primary objective was to describe patterns of systemic therapy use, and secondary endpoints included overall survival (OS) and real-world progression-free survival (PFS). Survival outcomes were estimated using the Kaplan–Meier method. Hazard ratios were estimated using Cox proportional hazards models. Exploratory analyses evaluated outcomes by treatment class. Results: A total of 66 patients were included; 55 received systemic therapy. Median follow-up was 192 months, and patients received a median of 2 treatment lines with heterogeneous sequencing. Median OS was 18 months (95% CI = 13.6 to 28.0). In first-line analyses, tyrosine kinase inhibitor–based therapy and immune checkpoint inhibitors were associated with improved OS compared with doxorubicin-based chemotherapy (tyrosine kinase inhibitor: hazard ratio [HR] = 0.33, 95% CI = 0.14 to 0.79; P = .01; immune checkpoint inhibitor: HR = 0.39, 95% CI = 0.10 to 0.94; P = .04). Median first-line real-world PFS was 3.8 months (95% CI = 2.9 to 6.3), with no statistically significant differences between treatment classes. Nondoxorubicin–based chemotherapy was associated with shorter real-world PFS compared with doxorubicin regimens (HR = 4.1, 95% CI = 1.71 to 9.83; P < .001). Conclusions: Metastatic clear cell sarcoma and gastrointestinal neuroectodermal tumor is highly aggressive with limited effective systemic options. Outcomes remain poor, highlighting the need for novel therapies and collaborative studies.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (20) , 4511-4513
Brightline-1: When a Negative Trial Reveals Two Active Therapies
Summary: Although Brightline-1 was headlined as a “negative trial,” brigimadlin showed clear biological activity, with the median PFS of 8.4 months, objective response rate of 22.3%, and translational evidence of p53 reactivation. Its failure largely reflects flawed control-arm assumptions, as doxorubicin outperformed retrospective expectations and established a new prospective benchmark in dedifferentiated liposarcoma. See related article by Schöffski et al., p. 4538
- 14 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (20) , 4511-4513
Open AccessBrightline-1: When a Negative Trial Reveals Two Active Therapies
Summary: Although Brightline-1 was headlined as a “negative trial,” brigimadlin showed clear biological activity, with the median PFS of 8.4 months, objective response rate of 22.3%, and translational evidence of p53 reactivation. Its failure largely reflects flawed control-arm assumptions, as doxorubicin outperformed retrospective expectations and established a new prospective benchmark in dedifferentiated liposarcoma. See related article by Schöffski et al., p. 4538
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma
Heatmaps of expression of 29 key gene signatures in (A) SARC028 and (B) Stanford RNA sequencing data
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma
Heatmaps of expression of 29 key gene signatures in (A) SARC028 and (B) Stanford RNA sequencing data
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma
Proportion of PBMC immunotypes in sarcoma, melanoma, and urothelial carcinoma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma
Proportion of PBMC immunotypes in sarcoma, melanoma, and urothelial carcinoma
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma
Purpose:Immune checkpoint blockade (ICB) benefits only a subset of patients with sarcoma. Biomarkers of response and resistance are needed to help guide patient selection.Experimental Design:We analyzed peripheral blood and tumor samples from patients with sarcoma treated in five ICB-based clinical trials. Baseline peripheral blood mononuclear cells (PBMC) underwent 11-color flow cytometry to define T-cell immunotypes. Baseline tumor tissue underwent RNA sequencing (RNA-seq) to classify tumors into four tumor microenvironment (TME) subtypes using consensus clustering of 29 functional gene expression signatures. Associations between immune features and clinical outcomes were assessed. A deep learning model was applied to baseline hematoxylin and eosin (H&E) slides to detect and quantify lymphoid aggregates in patients with available RNA-seq.Results:Among 178 patients with PBMC available for analysis, a proliferative (PRO) circulating T-cell immunotype was associated with poorer overall survival (OS) than lymphocyte-activation gene 3 (LAG)− or LAG+ immunotypes. RNA-seq from 67 tumors identified an immune-enriched/nonfibrotic TME subtype associated with a higher response rate, longer progression-free survival, and longer OS compared with immune-enriched/fibrotic, immune-depleted, and fibrotic subtypes. Automated analysis of 48 baseline H&E slides identified lymphoid aggregates in five tumors; four were classified as immune-enriched and two of these responded to ICB.Conclusions:Patients with sarcoma and a PRO circulating T-cell immunotype had inferior outcomes to ICB, whereas those with an immune-enriched/nonfibrotic TME had superior outcomes. Automated analysis of H&E slides showed promise in identifying patients with an immune-enriched TME. These findings support the use of a multimodal approach to identify predictors of response to immunotherapy in sarcoma.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma
Purpose:Immune checkpoint blockade (ICB) benefits only a subset of patients with sarcoma. Biomarkers of response and resistance are needed to help guide patient selection.Experimental Design:We analyzed peripheral blood and tumor samples from patients with sarcoma treated in five ICB-based clinical trials. Baseline peripheral blood mononuclear cells (PBMC) underwent 11-color flow cytometry to define T-cell immunotypes. Baseline tumor tissue underwent RNA sequencing (RNA-seq) to classify tumors into four tumor microenvironment (TME) subtypes using consensus clustering of 29 functional gene expression signatures. Associations between immune features and clinical outcomes were assessed. A deep learning model was applied to baseline hematoxylin and eosin (H&E) slides to detect and quantify lymphoid aggregates in patients with available RNA-seq.Results:Among 178 patients with PBMC available for analysis, a proliferative (PRO) circulating T-cell immunotype was associated with poorer overall survival (OS) than lymphocyte-activation gene 3 (LAG)− or LAG+ immunotypes. RNA-seq from 67 tumors identified an immune-enriched/nonfibrotic TME subtype associated with a higher response rate, longer progression-free survival, and longer OS compared with immune-enriched/fibrotic, immune-depleted, and fibrotic subtypes. Automated analysis of 48 baseline H&E slides identified lymphoid aggregates in five tumors; four were classified as immune-enriched and two of these responded to ICB.Conclusions:Patients with sarcoma and a PRO circulating T-cell immunotype had inferior outcomes to ICB, whereas those with an immune-enriched/nonfibrotic TME had superior outcomes. Automated analysis of H&E slides showed promise in identifying patients with an immune-enriched TME. These findings support the use of a multimodal approach to identify predictors of response to immunotherapy in sarcoma.